Vertex Tops Citi’s Biotech Picks After Crinetics Deal Completion

Citigroup analyst Geoff Meacham has identified Vertex Pharmaceuticals as a top biotech pick, following the company's strategic acquisition of Crinetics Pharmaceuticals for $10 billion in equity. This acquisition, cleared by regulators and approved by shareholders, solidifies Vertex's position in the endocrinology market. The deal brings immediate commercial revenue with PALSONIFY, the first once-daily oral therapy approved for acromegaly.

Additionally, the transaction preserves pipeline opportunities with atumelnant, currently in phase 3 for congenital adrenal hyperplasia and phase 2 for Cushing's syndrome. Endocrinology joins cystic fibrosis, hematology, pain, and renal as a key strategic growth platform for Vertex. Analysts project PALSONIFY sales of $700 million by 2030, with further upside potential from atumelnant.

Vertex maintains a Buy rating with a $585 price target. The company plans to discuss the financial impact of the transaction during its third quarter 2026 earnings call on November 2. As part of the acquisition, Vertex appointed Charles Wagner as Chief Operating Officer, responsible for the Crinetics integration, while Jonathan Poole became Chief Financial Officer starting January 1, 2027.

Jasper van Grunsven joined as Executive Vice President, Chief Pain and New Product Planning Officer on September 8. Vertex's investment potential was also highlighted by Bank of America, adding the company to its US 1 List of top investment ideas.